Gilead quarterly revenue rises 17% on remdesivir sales


Oct 28 (Reuters) - Gilead Sciences Inc GILD.O reported a 17% rise in quarterly revenue on Wednesday, helped by sales of its antiviral drug remdesivir, the first and only treatment approved in the United States for patients hospitalized with COVID-19.

Remdesivir brought in $873 million in the third quarter ended Sept. 30, below analysts' estimates of $960 million, according to Refinitiv IBES data.

Remdesivir, given intravenously, won formal U.S. approval last week, but the drug has been available under an FDA emergency use authorization since May.

Gilead's remdesivir gets U.S. FDA approval for hospitalized COVID-19 patients

Sales of first big COVID-19 drug, remdesivir, may disappoint

Gilead to buy cancer drugmaker Immunomedics for $21 bln

European countries face shortages of COVID-19 drug remdesivir

(Reporting by Vishwadha Chander in Bengaluru; Editing by Shounak Dasgupta)

((; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 6132))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.